Skip to main content
Interesting Articles

Regulatory Approval of Biosimilars in Canada

By August 31, 2018No Comments

The evolution and creation of new technologies, medications, and transformation of patient care continues to advance at an astonishing pace. With the advancement of medicine over the years we have seen how biologic drugs and treatments have transformed patient care. Biologics are therapies derived from living cells as opposed to traditional drug products which are mainly comprised of synthesized chemicals. Today, physicians use biologics in effectively treating common disorders such as diabetes, multiple sclerosis, various forms of cancer and several other diseases. Despite their effectiveness, biologics have two key drawbacks to their use, and that is their high cost, coupled with limited accessibility through provincial and territorial formularies for most patients. With the aging Canadian population, increased life span, prolonged need for continued health care and the need for more complex and expensive treatments, the increased healthcare costs are inevitable.